Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
News|Articles|March 9, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-04-06-2016
- Volume 11
- Issue 4
SGS Installs Immune Response Module in French Facility
Author(s)Pharmaceutical Technology Editors
The module was installed in the company’s Watson laboratory information management system in Poitiers, France.
Advertisement
SGS, a bio/pharmaceutical analytical and bioanalytical contract solutions provider, has fully installed and validated an immune response module (IRM) as part of its Watson laboratory information management system (LIMS), at its facility in Poitiers, France, according to a press announcement from the company.
According to SGS, the investment in the IRM is the latest strategic step for the company in its key business area of large molecule bioanalysis. The new module allows for faster immunogenicity data processing and easier consolidation of sample data. This allows bioanalytical studies to be managed by a single tool. The new module has been fully validated by SGS and can be used for good clinical practice and good laboratory practice compliant studies.
Source: SGS
Articles in this issue
over 10 years ago
Fundamentals for Pharma Agility and ROIover 10 years ago
Specialty API Manufacturers Invest for Growthover 10 years ago
Identifying Relevant Crystalline Formsover 10 years ago
Going Global Increases API Monitoring Burdenover 10 years ago
U.S. Representatives Question the Safety of the Heparin Supplyover 10 years ago
Biopharmaceutical Outsourcing Continues to Growover 10 years ago
CSafe Global Opens Atlanta Service Centerover 10 years ago
Article Details New 3D Modeling and Data Extraction Techniqueover 10 years ago
CMC Biologics and IDT Biologika Collaborate on ADC Manufacturingover 10 years ago
Vetter Breaks Ground on New Production FacilityAdvertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement